Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

WHO’s Interim recommendations for the use of One-dose Janssen Ad26.COV2.S (COVID-19) vaccine

Single dose of the vaccine can increase vaccine coverage rapidly which is an imperative in many countries where level of vaccine uptake is not optimal.  

WHO has updated its interim recommendations1 on the use of the Janssen Ad26.COV2.S (COVID-19).

One-dose schedule of the Janssen vaccine 

Use of either a one- or two-course of the Janssen vaccine can now be considered.  

The one-dose schedule is an EUL (Emergency Use Listing) authorized regimen. 

In some circumstances, using one dose may have advantages.  Many countries face severe vaccine supply constraints, combined with a high disease burden.  A single dose of the vaccine is efficacious and makes it possible to increase vaccine coverage rapidly, which in turn will reduce the burden on health care systems by preventing severe disease outcomes. A single dose may also be a preferred option for vaccinating hard-to-reach populations or populations living in conflict or insecure settings. 

Second dose of the vaccine:  

A second dose may be appropriate as vaccine supplies and/or accessibility increases. Countries should consider offering a second dose, beginning with the highest priority populations (e.g., healthcare workers, older people, people with comorbidities) as indicated in the WHO Prioritization Roadmap.  The administration of the second dose will result in increased protection against symptomatic infection, and against severe disease. 

A heterologous vaccine (e.g., a COVID-19 vaccine from another vaccine platform that has received EUL) can also be considered for the second dose. 

Interval between doses:  

Countries can also consider a longer interval between doses. A second dose 2 months after the initial dose substantially increases efficacy, especially against symptomatic infections, including when caused by SARS-CoV-2 variants of concern.  An even longer interval between the two doses with Ad26.COV2.S (6 months rather than 2 months) has been shown to result in a larger increase in immune responses in adults.  Countries could therefore consider an interval of up to 6 months based on their epidemiological situation, and needs of sub-populations. 

Comment:  

Like Oxford/AstraZeneca’s ChAdOx1, Janssen Ad26.COV2.S (COVID-19) vaccine also uses adenoviruses as vectors. There are evidences to link them to rare side effects of blood clot as they bind to platelet factor 4 (PF4), a protein implicated in the pathogenesis of clotting disorders2

***

Sources:  

  1. WHO 2021. Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine. Interim guidance Updated 9 December 2021. Available online at https://apps.who.int/iris/rest/bitstreams/1398839/retrieve  
  1. Soni R., 2021.Future of Adenovirus based COVID-19 Vaccines (such as Oxford AstraZeneca) in light of recent finding about Cause of rare side effects of Blood clot. Scientific European. Posted 03 December 2021. Available online here  

***

SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

DNA Origami Nanostructures for Treatment of Acute Kidney Failure

A novel study based on nanotechnology generates hope for...

Self-amplifying mRNAs (saRNAs): The Next Generation RNA Platform for Vaccines 

Unlike conventional mRNA vaccines which encodes only for the...

Diagnosing Vitamin D Deficiency by Testing Hair Sample Instead of Blood Test

Study shows first step towards developing a test for...
- Advertisement -
93,060FansLike
47,191FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe